The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

A Type D meeting was held with the FDA in March 2025 to discuss the potential regulatory path for OPGx-LCA5, including the ...

As of March 31, 2025, the Company's cash, cash equivalents and investments was $314.2 million. The Company expects that its ...

Under the title “Holistic pro-Inflammatory Target for Sight (HITS)” the Ophthalmology Pivotal Meeting kicked off in Saudi ...

Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients ...

President Donald Trump signed an Executive Order (EO) titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” aimed ...

In 2024 alone, Singapore secured S$13.5 billion in fixed asset investment commitments, with the biomedical sector ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Annou ...

Presented by The Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care   The Big Story PhRMA warns ...

The MOU aims to collaborate on enhancing public health services, awareness programs, and advancing disease management ...